News

Why You Should Consider Medicare Supplement Plans

A program of the federal government, Medicare provides healthcare insurance and benefits to the eligible population, which includes those who are 65 years old and above, with disabilities, and with end-stage renal disease. The Original Medicare has two parts: Part...

A 3-Dose Vaccine Can Protect HIV Patients From hepatitis B

A three-dose series of the HEPLISAV-B vaccine protects against hepatitis B virus (HBV) in HIV patients who have not received a prior vaccination against the virus or who are not afflicted with it, according to clinical trial findings achieved...

Latest Study From ICR Monitors Unusual Cancer In Children

The researchers discovered that liquid biopsy blood tests may detect symptoms of a malignancy that has reappeared, evaluate the severity of the condition, and assist in determining the best treatment option for specific individuals. RMS is an uncommon form of...

Micro-Sphere Expands HPAPI Capabilities at Swiss Site

Spray drying specialist and capsule filling service contract development and manufacturing organisation (CDMO) Micro-Sphere has invested over €5 million to expand its GMP manufacturing capabilities at its facility in Monteggio, Switzerland. The investment sees the Swiss site benefit from infrastructure...

CDC Suggests Pairing Novavax COVID Shot With Pfizer, Moderna

The Centers for Disease Control and Prevention on October 19 advised adults in the United States to take Covid boosters from Novavax, even those who had received their primary round of doses from Pfizer, Moderna, or Johnson & Johnson. Adults 18...

FDA To Fund $38 Million To Fuel 4-Year Rare Disease Research

A total of $38 million has been granted by the US Food and Drug Administration (FDA) in the form of 19 new grants and two new contracts to support the forthcoming four years of clinical trial trials and regulatory...

Over Five Years, Clinical Studies In The UK Have Plunged

An industry analysis on October 20th revealed that the number of clinical trials launched annually in Britain decreased by 41% between 2017 and 2021, creating a "clear and significant threat" to its reputation as a destination for clinical research. The...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read